Other content in this Stream
From enabling the manufacturing of biopharmaceuticals to developing its own drug pipeline.
Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for...
Q2 Webcast 15th August 2018
Prometic reports second quarter 2018 financial results and highlights
Quarterly Report Q2 2018
Quarterly Report Q1 2018
Prometic reports its 2018 first quarter highlights and financial results
Annual Information Form 2017
Prometic Annual Information Form 2017
Corporate Governance and Nominating Committee Charter 2017
Board of Directors Charter 2017
Audit, Risk and Finance Committee Charter 2017
Chairman Mandate 2018
Virtual Tour of Prometic Life Science's Manufacturing Process
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment